Theon Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Theon Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $14.2M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Theon Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $14.2M Trade | TransData Nexus

Theon Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Advanced Antibiotics Specialist · $14.2M Total Trade · DGFT Verified

Theon Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $14.2M across 4 products in 1 therapeutic categories. Based on 1,115 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Cefuroxime ($7.5M), Ceftriaxone ($6.3M), Ceftazidime ($338.3K).

Theon Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Theon Pharmaceuticals Limited pharmaceutical export portfolio — 4 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Theon Pharmaceuticals Limited? — Company Overview & Market Position

Theon Pharmaceuticals Limited, established on May 26, 2005, is a public unlisted company headquartered in Chandigarh, India. The company is classified under the Corporate Identification Number (CIN) U24231CH2005PLC028465. Its authorized share capital is ₹50 million, with a paid-up capital of ₹43.75 million. Theon Pharmaceuticals specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. The company is committed to quality, adhering to WHO-GMP and ISO 9001:2008 standards, ensuring that its products meet international quality benchmarks.

Theon Pharmaceuticals operates a state-of-the-art manufacturing facility located in the excise-free zone of Himachal Pradesh, India. This facility spans 4.5 acres and is equipped with modern infrastructure for the production of tablets, capsules, injectables, and dry syrup formulations. The plant has an impressive annual production capacity, including 2,000 million tablets, 1,000 million capsules, 100 million injectables, and 50 million dry syrup units. The company's product portfolio is diverse, encompassing therapeutic segments such as antibiotics, anti-inflammatory agents, and anti-diabetics. Theon Pharmaceuticals exports its products to over 60 countries, including regions in Africa, Southeast Asia, Latin America, and the CIS countries, reflecting its significant global presence.

What Does Theon Pharmaceuticals Limited Export? — Product Portfolio Analysis

Product Portfolio — Top 4 by Export Value

Theon Pharmaceuticals Limited exports 4 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Cefuroxime	Advanced Antibiotics	$7.5M	586	5.8%	5
2	Ceftriaxone	Advanced Antibiotics	$6.3M	503	2.2%	10
3	Ceftazidime	Advanced Antibiotics	$338.3K	23	3.2%	4
4	Roxithromycin	Advanced Antibiotics	$46.9K	3	1.1%	10

Theon Pharmaceuticals Limited exports 4 pharmaceutical products across 1 therapeutic categories with a total export value of $14.2M. The top category is Advanced Antibiotics (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Theon Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Theon Pharmaceuticals Limited's manufacturing facility is strategically located in the excise-free zone of Himachal Pradesh, India. This location offers tax advantages and operational efficiencies, contributing to the company's competitive edge in the pharmaceutical manufacturing sector. The plant is segmented into dedicated blocks for General formulations, Penicillins (Beta Lactams), and Cephalosporins, ensuring specialized production environments that adhere to stringent quality standards. Theon Pharmaceuticals has recently expanded its capabilities with the addition of a Dry Powder Injectable manufacturing facility, fully compliant with all regulatory and statutory requirements. This expansion underscores the company's commitment to meeting diverse market needs and adhering to global quality standards.

3Key Leadership

Theon Pharmaceuticals Limited is led by a team of experienced professionals committed to the company's mission of delivering high-quality pharmaceutical products. The leadership team includes:

Mr. Amit Bansal: CEO
Mr. Punit Bansal: Director
Mr. Anshul Bansal: Director
Mr. Manish Bansal: Director

These leaders bring a wealth of experience and strategic vision to the company, driving its growth and ensuring adherence to quality standards.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Theon Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Theon Pharmaceuticals Limited has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and certifications to access these markets, demonstrating its commitment to meeting international standards. In the United States, Theon Pharmaceuticals has registered its manufacturing facilities with the FDA, ensuring compliance with Good Manufacturing Practices (GMP). The company has also filed Abbreviated New Drug Applications (ANDAs) for its generic formulations, facilitating market entry. In the European Union, Theon Pharmaceuticals has obtained EU GMP certificates, allowing it to market its products across EU member states. The company is also in the process of obtaining approvals from other regulatory bodies, such as the UK's MHRA, Australia's TGA, and Japan's PMDA, to further expand its market reach. These efforts reflect Theon Pharmaceuticals' strategic focus on penetrating regulated markets and adhering to their stringent regulatory requirements.

2Emerging Markets

Theon Pharmaceuticals Limited has strategically expanded its footprint into emerging markets, including regions in Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has been instrumental in facilitating access to these markets, as it ensures that products meet international quality benchmarks. By obtaining WHO prequalification, Theon Pharmaceuticals has enhanced its credibility and trustworthiness among healthcare providers and regulatory authorities in these regions. This strategic approach has enabled the company to establish a strong presence in emerging markets, contributing to its overall growth and global reach.

Theon Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Theon Pharmaceuticals Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with the agency's Good Manufacturing Practices (GMP). The company has also filed Abbreviated New Drug Applications (ANDAs) for its generic formulations, facilitating market entry into the U.S. market. These regulatory filings demonstrate Theon Pharmaceuticals' commitment to meeting the stringent requirements set forth by the FDA, reflecting its dedication to quality and regulatory compliance. The company's proactive approach in obtaining FDA approvals positions it favorably in the competitive U.S. pharmaceutical market.

2WHO & EU GMP

Theon Pharmaceuticals Limited has obtained WHO-GMP certification, affirming its adherence to international quality standards in pharmaceutical manufacturing. This certification is crucial for accessing global markets and underscores the company's commitment to quality. In addition to WHO-GMP, Theon Pharmaceuticals has secured EU GMP certificates, enabling it to market its products across European Union member states. These certifications reflect the company's dedication to maintaining high manufacturing standards and its strategic focus on expanding its presence in regulated markets.

CDSCO & Indian Regulatory

Theon Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Theon Pharmaceuticals Limited operates in a competitive landscape, with several key players in the pharmaceutical manufacturing sector. While specific market share data is not publicly available, Theon Pharmaceuticals distinguishes itself through its WHO-GMP and ISO 9001:2008 certifications, extensive product portfolio, and strategic focus on both domestic and international markets. The company's commitment to quality and regulatory compliance positions it favorably against competitors, enabling it to capture a significant share of the global pharmaceutical market.

2Key Differentiators

Theon Pharmaceuticals Limited's key differentiators include its adherence to WHO-GMP and ISO 9001:2008 standards, ensuring high-quality manufacturing processes. The company's diverse product portfolio, encompassing various therapeutic segments, allows it to meet a wide range of market needs. Additionally, Theon Pharmaceuticals' strategic focus on obtaining regulatory approvals in multiple regions, including the U.S., EU, and emerging markets, enhances its global reach and credibility. These factors collectively contribute to the company's competitive advantage in the pharmaceutical industry.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Theon Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Theon Pharmaceuticals Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a significant export volume and consistency in product quality. The company's adherence to WHO-GMP and ISO 9001:2008 standards underscores its commitment to maintaining high

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — Theon Pharmaceuticals Limited

How many pharmaceutical products does Theon Pharmaceuticals Limited export from India?

Theon Pharmaceuticals Limited exports 4 pharmaceutical products across 1 therapeutic categories. The top exports are Cefuroxime ($7.5M), Ceftriaxone ($6.3M), Ceftazidime ($338.3K), Roxithromycin ($46.9K). Total export value is $14.2M.

What is Theon Pharmaceuticals Limited's total pharmaceutical export value?

Theon Pharmaceuticals Limited's total pharmaceutical export value is $14.2M, based on 1,115 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Theon Pharmaceuticals Limited cover?

Theon Pharmaceuticals Limited exports across 1 therapeutic categories. The largest are Advanced Antibiotics (100.0%, 4 products).

Get Full Theon Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.